Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 31;10(1):1873530. doi: 10.1080/2162402X.2021.1873530

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 2. — ADCC is enhanced in ECP responders

(a) Boxplots showing the efficacy of antibody-dependent cellular cytotoxicity (ADCC) in arbitrary units (AU) for healthy individuals and Sézary patients before and after ECP treatment (Tx), n = 12 for all groups, ns = not significant. A significant increase (p = .004) is detected after ECP therapy. (b) Dot plot presenting the same data as in a) for individual Sézary patients, showing great interpatient variability in response to ECP treatment. (c) Bar plots showing fold changes in ADCC of Sézary patients after ECP treatment. ECP clinical responders in red, non-responders in black. (d) Box plots showing the efficacy of ADCC after ECP in arbitrary units (AU) for healthy individuals and Sézary patients split into non-responders and responders. While the difference in non-reponders in not significant (ns), responders show a significant increase (p = .02422) in ADCC compared to healthy.